<p>Prostate cancer (PC) is one of the most burning problems of modern urologic oncology because the incidence of this pathology remains high now. Castration-refractory PC (CRPC) is an extremely heterogeneous disease whose prognosis is largely determined by a number of factors, including the number and site of distant metastases. In the patients with CRPC, distant metastases are verified with the highest frequency in the bones, lymph nodes, and lung. Atypical metastatic involvement cases are rarely observed in patients with CRPC. The paper gives a review of literature and describes a clinical case of the atypical site of metastasis in a patient with CRPC.</p><p> </p
Objective: This study focuses on a case report on a patient with renal carcinoma who developed metas...
peer reviewedProstate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous...
Colorectal cancer (CRC) is a common clinical entity. A significant proportion of patients experience...
Abstract Background In most cases, prostate cancer metastasizes to the lymph nodes, bone, and liver....
AbstractUreteral metastasis from prostate cancer is rare. Here, we report a case of ureteral metasta...
Prostate carcinoma is a very rare origin of metastatic disease in the ureter. We report a case of a ...
Prostate carcinoma is a very rare origin of metastatic disease in the ureter. We report a case of a ...
Within the text we describe a 66-year-old male with a history of prostate cancer (PCa), incidentally...
In patients with prostate cancer, metastases mostly develop in bone, lung, liver, pleura and adrenal...
Copyright © 2014 Tian-bao Huang et al. This is an open access article distributed under the Creative...
AbstractProstate cancer is very frequent, but secondary ureteral metastasis are extremely rare. We p...
Prostate cancer is very frequent, but secondary ureteral metastasis are extremely rare. We present a...
Abstract Background The most common metastatic sites of prostate cancer are the lymph nodes and bone...
AbstractUreteral metastasis from prostate cancer is rare. Here, we report a case of ureteral metasta...
Introduction: Prostatic carcinoma has variable course of disease progression. Patients with metasta...
Objective: This study focuses on a case report on a patient with renal carcinoma who developed metas...
peer reviewedProstate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous...
Colorectal cancer (CRC) is a common clinical entity. A significant proportion of patients experience...
Abstract Background In most cases, prostate cancer metastasizes to the lymph nodes, bone, and liver....
AbstractUreteral metastasis from prostate cancer is rare. Here, we report a case of ureteral metasta...
Prostate carcinoma is a very rare origin of metastatic disease in the ureter. We report a case of a ...
Prostate carcinoma is a very rare origin of metastatic disease in the ureter. We report a case of a ...
Within the text we describe a 66-year-old male with a history of prostate cancer (PCa), incidentally...
In patients with prostate cancer, metastases mostly develop in bone, lung, liver, pleura and adrenal...
Copyright © 2014 Tian-bao Huang et al. This is an open access article distributed under the Creative...
AbstractProstate cancer is very frequent, but secondary ureteral metastasis are extremely rare. We p...
Prostate cancer is very frequent, but secondary ureteral metastasis are extremely rare. We present a...
Abstract Background The most common metastatic sites of prostate cancer are the lymph nodes and bone...
AbstractUreteral metastasis from prostate cancer is rare. Here, we report a case of ureteral metasta...
Introduction: Prostatic carcinoma has variable course of disease progression. Patients with metasta...
Objective: This study focuses on a case report on a patient with renal carcinoma who developed metas...
peer reviewedProstate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous...
Colorectal cancer (CRC) is a common clinical entity. A significant proportion of patients experience...